TY - JOUR T1 - Eosinopenia in COPD patients with severe acute respiratory virus 2 (Sars-CoV-2) infection as a potential fatal outcome predictor JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA961 VL - 58 IS - suppl 65 SP - PA961 AU - Jane-Erica Paluero AU - Lemar Tokhi AU - Mihovil Roglic AU - Marina Labor Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA961.abstract N2 - Eosinophils contribute to innate antiviral immunity of the lung and eosinophilic blood count can be used as an early, effective and relevant biomarker predicting high disease severity in COPD patients with Sars-CoV-2 infection. Aim was to investigate the diagnostic and prognostic value of eosinopenia in Covid-19 positive COPD patients. Retrospective pilot study based on medical record review was performed on patients admitted for hospital treatment from the start of pandemic in March 2020 till end of January 2021. All patients had a positive PCR test at the moment of admission and COPD diagnose was confirmed from the medical record. Absolute eosinophile count was taken at the moment of admission. Study involved 23 COPD patients of which 43.48% were male with a median age of 82 (74-85) years. Total mortality was 43.48% with a 95% confidence interval between 23.19%-65.51%. Patients who died had significantly higher values of total leukocytes, C-reactive protein and procalcitonin compared to survivors, and lower values of eosinophils. Mean absolute eosinophile count in patients who died was 1.2±2.69, and in survivors 4.7±8.73 (d=0.54). The mean FEV1 value 55.1% (1.35 L) and FVC 72.08% (2.34 L) before Sars-CoV-2 infection. Allmost all subjects required oxygen therapy (95.65%), of which 17.39% high-flow nasal oxygen therapy and 8.7% invasive mechanical ventilation. The median duration of supportive respiratory therapy was 6 (4-12) days. A moderate effect size was observed in the absolute eosinophile between survived COPD patients. Our finding suggest that eosinopenia in COPD-Sars-CoV-2 positive patients may be a potential predictor for fatal outcome.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA961.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -